US 11596694
Compositions and methods for predicting response to NaPi2b-targeted therapy
granted A61KA61K2039/505A61K47/68031
Quick answer
US patent 11596694 (Compositions and methods for predicting response to NaPi2b-targeted therapy) held by Mersana Therapeutics, Inc. expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mersana Therapeutics, Inc.
- Grant date
- Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K47/68031, A61K47/6849, A61K47/6857